Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

B cells are associated with survival and immunotherapy response in sarcoma

Open access

Abstract

Soft-tissue sarcomas represent a heterogeneous group of cancer, with more than 50 histological subtypes1,2. The clinical presentation of patients with different subtypes is often atypical, and responses to therapies such as immune checkpoint blockade vary widely3,4. To explain this clinical variability, here we study gene expression profiles in 608 tumours across subtypes of soft-tissue sarcoma. We establish an immune-based classification on the basis of the composition of the tumour microenvironment and identify five distinct phenotypes: immune-low (A and B), immune-high (D and E), and highly vascularized (C) groups. In situ analysis of an independent validation cohort shows that class E was characterized by the presence of tertiary lymphoid structures that contain T cells and follicular dendritic cells and are particularly rich in B cells. B cells are the strongest prognostic factor even in the context of high or low CD8+ T cells and cytotoxic contents. The class-E group demonstrated improved survival and a high response rate to PD1 blockade with pembrolizumab in a phase 2 clinical trial. Together, this work confirms the immune subtypes in patients with soft-tissue sarcoma, and unravels the potential of B-cell-rich tertiary lymphoid structures to guide clinical decision-making and treatments, which could have broader applications in other diseases. Immune profiling of the tumour microenvironment of soft-tissue sarcoma identifies a group of patients with high levels of B-cell infiltration and tertiary lymphoid structures that have improved survival and a high response rate to immune checkpoint blockade therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41586-019-1906-8

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 40 references

Cited by

See all 1,942

Metadata

Authors
Petitprez, F., de Reyniès, A., Keung, E. Z., Chen, T. W.-W., Sun, C.-M., Calderaro, J., Jeng, Y.-M., Hsiao, L.-P., Lacroix, L., Bougoüin, A., Moreira, M., Lacroix, G., Natario, I., Adam, J., Lucchesi, C., Laizet, Y., Toulmonde, M., Burgess, M. A., Bolejack, V., Reinke, D., Wani, K. M., Wang, W.-L., Lazar, A. J., Roland, C. L., Wargo, J. A., Italiano, A., Sautès-Fridman, C., Tawbi, H. A., & Fridman, W. H.
Affiliations
  • Inserm (FR)
  • The University of Texas MD Anderson Cancer Center (US)
  • National Taiwan University (TW)
  • National Taiwan University Hospital (TW)
  • Institut Gustave Roussy (FR)
  • Institut Bergonié (FR)
  • University of Pittsburgh (US)
  • Cancer Research And Biostatistics (US)
  • Sarcoma Alliance for Research through Collaboration (US)
Corresponding author
  • Tawbi, Hussein A.
  • Fridman, Wolf H.
Venue
Nature
Published
2020-01-15
Volume
577
Issue
7791
Pages
556-560
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W3000282923
Cited by
1,942
References
40
Citations by year
2026: 215 · 2025: 257 · 2024: 304 · 2023: 308 · 2022: 330 · 2021: 335 · 2020: 189
FWCI
167.49
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, other-oa)
  • RePEc: Research Papers in Economics (submittedVersion)
Funders
  • Association pour la Recherche sur le Cancer
  • Agence Nationale de la Recherche (ANR-10-LABX-0015)
  • Institut National de la Santé et de la Recherche Médicale (UMRS1138)
  • National Taiwan University Hospital
  • Institut National Du Cancer
  • National Taiwan University
  • Sorbonne Université
  • Université de Paris
  • National Institutes of Health (T32CA0095999)
  • University of Texas MD Anderson Cancer Center
  • Labex Immuno-Oncology (LAXE62_9UMRS972 FRIDMAN, LAXE62_9UMRS972)
  • National Cancer Institute (T32CA009599, K12CA088084)
Topics
  • Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
Keywords
soft tissue sarcoma, B cells, tertiary lymphoid structures, tumor microenvironment, immune checkpoint blockade, pembrolizumab, anti-PD-1 therapy, immunotherapy response, prognostic factors, gene expression profiling, follicular dendritic cells, CD8+ T cells, survival
MeSH terms
Tertiary Lymphoid Structures, B-Lymphocytes, Humans, Immunotherapy, Mutation, Phenotype, Prognosis, Sarcoma, Reproducibility of Results, Cohort Studies, Survival Rate, CD8-Positive T-Lymphocytes, Dendritic Cells, Follicular, Tumor Microenvironment, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: B cells are associated with survival and immunotherapy response in sarcoma. https://app.cochat.ai/papers/10.1038/s41586-019-1906-8
The paper
Petitprez, F., de Reyniès, A., Keung, E. Z., Chen, T. W.-W., Sun, C.-M., Calderaro, J., Jeng, Y.-M., Hsiao, L.-P., Lacroix, L., Bougoüin, A., Moreira, M., Lacroix, G., Natario, I., Adam, J., Lucchesi, C., Laizet, Y., Toulmonde, M., Burgess, M. A., Bolejack, V., . . . Fridman, W. H. (2020). B cells are associated with survival and immunotherapy response in sarcoma. Nature. https://doi.org/10.1038/s41586-019-1906-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.